Veracyte on Tuesday reported second quarter (end-June 30) total revenues of $72.9 million, an increase of 32% compared to $55.1 million in Q2 2021.
In the most recent quarter, Veracyte posted testing revenues of $59.7 million, an increase of 18% compared to $50.8 million in Q2 2021, driven primarily by the strong performance of its urology tests.
Product revenue in the second quarter of 2022 was $3.1 million, an increase of 16% compared to $2.7 million in the same period of 2021.
Its Q2 biopharmaceutical and other revenue was $10 million, compared to $1.6 million in the prior-year period, an increase driven primarily by the acquisition of HalioDx.
The company's Q2 net loss widened to $9.5 million from $9.0 million in Q2 2021.